FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224003315> ?p ?o ?g. }

• W4224003315 abstract "Background: Osteoarthritis (OA) is a degenerative disease which serious affects patients. Ligusticum chuanxiong (CX) has been shown to have a certain curative effect on osteoarthritis in traditional Chinese medicine therapy. This study is based on network pharmacology and molecular docking technology to explore the potential mechanism of CX. Methods: Components of CX to treat osteoarthritis were screened in the TCMSP database and targets were predicted by the PharmMapper database, the osteoarthritis targets were collected from the GeneCards database, and intersection genes were found to be the possible targets of CX anti-OA. The STRING database and Cytoscape software were utilized for protein-protein interaction analysis and further screening of core targets. The Metascape database was used for KEGG and GO enrichment analyses. Then, the top 10 pathways were selected to construct drug-compound-target-pathway-disease network analysis. Finally, molecular docking was used to analyze the binding affinity of seven compounds with core targets and TNF-α. Results: Seven compounds with 253 non-repetitive targets of CX were screened from the TCMSP database and 60 potential intersection targets of CX anti-OA were found. PPI network analysis showed that the core targets were ALB, AKT1, IGF1, CASP3, MAPK1, ANXA5, and MAPK14, while GO and KEGG pathway enrichment analyses showed that the relevant biological processes involved in the treatment of osteoarthritis by CX might include the MAPK cascade and reactive oxygen species metabolic process. The KEGG pathway analysis result was mainly associated with the MAPK signaling pathway and PI3K-AKT signaling pathway. We further docked seven ingredients with MAPK1 and MAPK14 enriched in the MAPK pathway, and TNF-α as the typical inflammatory cytokine. The results also showed good binding affinity, especially FA, which may be the most important component of CX anti-OA. Conclusion: Our research revealed the potential mechanism of CX in the treatment of OA, and our findings can also pave the way for subsequent basic experimental verification and a new research direction." @default.
• W4224003315 created "2022-04-19" @default.
• W4224003315 creator A5007707620 @default.
• W4224003315 creator A5011892455 @default.
• W4224003315 creator A5023801499 @default.
• W4224003315 creator A5030990400 @default.
• W4224003315 creator A5033735375 @default.
• W4224003315 creator A5041477172 @default.
• W4224003315 creator A5050650910 @default.
• W4224003315 creator A5064095491 @default.
• W4224003315 creator A5065859286 @default.
• W4224003315 creator A5077329616 @default.
• W4224003315 date "2022-04-14" @default.
• W4224003315 modified "2023-10-03" @default.
• W4224003315 title "Network Pharmacology and Molecular Docking to Elucidate the Potential Mechanism of Ligusticum Chuanxiong Against Osteoarthritis" @default.
• W4224003315 cites W1976194786 @default.
• W4224003315 cites W1987495412 @default.
• W4224003315 cites W1995223915 @default.
• W4224003315 cites W2009007518 @default.
• W4224003315 cites W2021987372 @default.
• W4224003315 cites W2033591223 @default.
• W4224003315 cites W2069096810 @default.
• W4224003315 cites W2101078720 @default.
• W4224003315 cites W2104916446 @default.
• W4224003315 cites W2114128492 @default.
• W4224003315 cites W2124679671 @default.
• W4224003315 cites W2132629607 @default.
• W4224003315 cites W2134739627 @default.
• W4224003315 cites W2145825918 @default.
• W4224003315 cites W2151155970 @default.
• W4224003315 cites W2169678694 @default.
• W4224003315 cites W2244481220 @default.
• W4224003315 cites W2276691000 @default.
• W4224003315 cites W2313408064 @default.
• W4224003315 cites W2492722291 @default.
• W4224003315 cites W2522813771 @default.
• W4224003315 cites W2546525825 @default.
• W4224003315 cites W2577634437 @default.
• W4224003315 cites W2596302024 @default.
• W4224003315 cites W2746683901 @default.
• W4224003315 cites W2782189204 @default.
• W4224003315 cites W2789964320 @default.
• W4224003315 cites W2792701691 @default.
• W4224003315 cites W2884431837 @default.
• W4224003315 cites W2885079199 @default.
• W4224003315 cites W2898391595 @default.
• W4224003315 cites W2913535172 @default.
• W4224003315 cites W2917075888 @default.
• W4224003315 cites W2928665623 @default.
• W4224003315 cites W2939616219 @default.
• W4224003315 cites W2945274796 @default.
• W4224003315 cites W2969443468 @default.
• W4224003315 cites W2979872515 @default.
• W4224003315 cites W2988065300 @default.
• W4224003315 cites W2996774074 @default.
• W4224003315 cites W2997274725 @default.
• W4224003315 cites W3006303310 @default.
• W4224003315 cites W3008149695 @default.
• W4224003315 cites W3016247086 @default.
• W4224003315 cites W3046622411 @default.
• W4224003315 cites W3049709065 @default.
• W4224003315 cites W3092040250 @default.
• W4224003315 cites W3119439244 @default.
• W4224003315 cites W3119762460 @default.
• W4224003315 cites W3128653999 @default.
• W4224003315 cites W3136663431 @default.
• W4224003315 cites W3142465436 @default.
• W4224003315 cites W3162538759 @default.
• W4224003315 cites W4206835536 @default.
• W4224003315 cites W4210254819 @default.
• W4224003315 doi "https://doi.org/10.3389/fphar.2022.854215" @default.
• W4224003315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35496280" @default.
• W4224003315 hasPublicationYear "2022" @default.
• W4224003315 type Work @default.
• W4224003315 citedByCount "13" @default.
• W4224003315 countsByYear W42240033152022 @default.
• W4224003315 countsByYear W42240033152023 @default.
• W4224003315 crossrefType "journal-article" @default.
• W4224003315 hasAuthorship W4224003315A5007707620 @default.
• W4224003315 hasAuthorship W4224003315A5011892455 @default.
• W4224003315 hasAuthorship W4224003315A5023801499 @default.
• W4224003315 hasAuthorship W4224003315A5030990400 @default.
• W4224003315 hasAuthorship W4224003315A5033735375 @default.
• W4224003315 hasAuthorship W4224003315A5041477172 @default.
• W4224003315 hasAuthorship W4224003315A5050650910 @default.
• W4224003315 hasAuthorship W4224003315A5064095491 @default.
• W4224003315 hasAuthorship W4224003315A5065859286 @default.
• W4224003315 hasAuthorship W4224003315A5077329616 @default.
• W4224003315 hasBestOaLocation W42240033151 @default.
• W4224003315 hasConcept C104317684 @default.
• W4224003315 hasConcept C142724271 @default.
• W4224003315 hasConcept C150194340 @default.
• W4224003315 hasConcept C152724338 @default.
• W4224003315 hasConcept C154137905 @default.
• W4224003315 hasConcept C155261790 @default.
• W4224003315 hasConcept C159110408 @default.
• W4224003315 hasConcept C162317418 @default.
• W4224003315 hasConcept C204787440 @default.
• W4224003315 hasConcept C2776164576 @default.
• W4224003315 hasConcept C2779446555 @default.

• next